[Preparation of anti-zearalenone monoclonal antibody and preliminary establishment of colloidal gold immunochromatographic assay for zearalenone].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

Guangdong Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou 510632, China.

Published: July 2013

Objective: To prepare the monoclonal antibody against zearalenone (ZEN) toxin and preliminarily establish the colloidal gold immunochromatographic detection method for ZEN.

Methods: The artificial antigen ZEN-BSA and ZEN-OVA were prepared by active ester method. Mice were immunized with ZEN-OVA and monoclonal antibodies against ZEN were prepared by regular cell fusion and subcloning approach. The titer, subtype and specificity of the antibodies were identified by ELISA. To establish a method of colloidal gold immunochromatographic assay (GICA) for the determination of ZEN, colloidal gold binding cushion was coated with anti-ZEN monoclonal antibody-colloidal gold complex, and the synthetic ZEN-BSA and goat anti-mouse immunoglobulins were sprayed on cellulose nitrate film to form the test (T) band and control (C) band.

Results: Identified by SDS-PAGE and UV spectroscopy, the artificial antigen ZEN-BSA and ZEN-OVA were successfully coupled respectively. One hybridoma line (1G4) which could secrete monoclonal antibody specifically against ZEN was obtained by three-time cloning. The ascites titer of this monoclonal antibody reached 1:1.6×10(5);. The antibody subtype was IgG2b. The IC50; to ZEN was 10.2 ng/mL, and the detction limit was 0.58 ng/mL. In addition, the mAb was proved highly specific for ZEN. ZEN metabolites α-zearalanol, β-zearalanol, zearalanone and other similar toxins deoxynivalenol, fumonisin B1, ochratoxin A showed very low or no cross-activity with the monoclonal antibody. The whole assay using the prepared colloidal gold immunochromatographic strip could be finished in 5 min, which could be read by naked eyes. The limit of detection was 100 ng/mL.

Conclusion: The anti-ZEN mAb was successfully prepared. And the gold immunochromatographic assay(GICA) for ZEN was preliminarily established with the limit of detection being 100 ng/mL.

Download full-text PDF

Source

Publication Analysis

Top Keywords

monoclonal antibody
20
colloidal gold
20
gold immunochromatographic
20
immunochromatographic assay
8
zen
8
artificial antigen
8
antigen zen-bsa
8
zen-bsa zen-ova
8
limit detection
8
detection 100
8

Similar Publications

P-cadherin, a crucial cell-cell adhesion protein which is overexpressed in numerous malignant cancers, is a popular target for drug delivery antibodies. However, molecular guidelines for engineering antibodies that can be internalized upon binding to P-cadherin are unknown. Here, we use a combination of biophysical, biochemical, and cell biological methods to demonstrate that trapping the P-cadherin extracellular region in an X-dimer adhesive conformation triggers cadherin endocytosis via an outside-in signaling mechanism.

View Article and Find Full Text PDF

Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead.

Semin Hematol

December 2024

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

Recent advancements in multiple myeloma (MM) treatment-including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and T cell-redirecting therapies like chimeric antigen receptor (CAR) T cells and bispecific antibodies (BsAbs)-have significantly improved patient outcomes. However, MM remains incurable, highlighting the need for novel therapeutic strategies. BsAbs, which simultaneously target a tumor-specific antigen and CD3 on T cells, have shown promising efficacy.

View Article and Find Full Text PDF

This study demonstrates the analytical and clinical validity of the approved (United States and Japan) plasma-based Guardant360 companion diagnostic (CDx) test for selecting patients with human epidermal growth factor receptor 2 (HER2 [ERBB2])-mutated (HER2m) non-small-cell lung cancer (NSCLC) for trastuzumab deruxtecan (T-DXd) treatment. Concordance between the Guardant360 CDx test and the plasma-based AVENIO ctDNA Expanded Kit Assay (AVENIO), as well as the tissue-based clinical trial assays (CTAs) was investigated. Clinical utility was assessed by comparing T-DXd clinical efficacy results of patients in DESTINY-Lung01/02 who tested positive for HER2 mutations using the Guardant360 CDx test to benchmark efficacy results from DESTINY-Lung01/02.

View Article and Find Full Text PDF

Objective: To compare work loss after starting tumour necrosis factor inhibitors (TNFi), rituximab, abatacept or tocilizumab in patients with rheumatoid arthritis (RA).

Methods: We used data from the Swedish Rheumatology Quality Register to identify patients aged 19-62 years who were treated with TNFi (n=15 093), rituximab (n=2123), abatacept (n=1877) or tocilizumab (n=1720) between 2007 and 2020. Data on work loss (0-365 days per year) from sick leave and disability pension were retrieved from linkage to the Social Insurance Agency.

View Article and Find Full Text PDF

FSH exacerbates bone loss by promoting osteoclast energy metabolism through the CREB-MDH2-NAD axis.

Metabolism

January 2025

State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, PR China. Electronic address:

Aims: Osteoclast energy metabolism is a promising target for treating diseases characterized by high osteoclast activity, such as osteoporosis. However, the regulatory factors involved in osteoclast bioenergetic processes are still in the early stages of being fully understood. This study reveals the effects of follicle-stimulating hormone (FSH) on osteoclast energy metabolism.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!